How (and why) the immune system makes us sleep by L. Imeri & M.R. Opp
Modern sleep research began in 1953, with the discovery 
of rapid eye movement (REM) sleep and the realization 
that sleep is an active process that consists of two distinct 
phases. More than half a century of intense investigation 
has yet to provide an unequivocal answer to the ques‑
tion, ‘Why do we sleep?’ Nonetheless, we are beginning 
to understand the contribution of sleep to fundamental 
brain processes1,2.
In contrast to our lack of knowledge regarding the 
precise functions of sleep, we do know why we have an 
immune system. Living organisms are subject to constant 
attack by various pathogens, and the complex networks 
of physical and biochemical components that constitute 
the immune system keep the organism alive. Like sleep 
research, the field of immunology is a relatively young 
discipline. It should therefore not come as a surprise that 
systematic investigations of interactions between sleep 
and the immune system have only been conducted in 
the past 25 years (Timeline).
Although we briefly touch on the general role of 
sleep in health and disease, in this Review we focus on 
those areas of research that are most relevant to sleep 
as a component of the host defence against microbial 
pathogens. Links between the CNS and the peripheral 
immune system are now well established, and much is 
known about the mechanisms by which bidirectional 
communication occurs between these systems3. As a 
result of neuro–immune interactions, sleep loss alters 
immune function and immune challenges alter sleep. 
Thus, chronic sleep loss results in pathologies that are 
associated with increases in inflammatory mediators, 
and inflammatory mediators that are released during 
immune responses to infection alter CNS processes and 
behaviour, including sleep.
One class of immunomodulators, cytokines, has been 
extensively studied both with respect to host responses 
to infection and as regulators of physiological sleep. In 
this Review, we briefly summarize what is known about 
cytokines in the brain as regulators of normal, physiolog‑
ical sleep and what is known about their role in mediat‑
ing the changes in sleep that are induced by infectious 
agents. We focus on one cytokine, interleukin 1 (IL‑1), 
which, together with tumour necrosis factor (TNF), is 
the most investigated cytokine with respect to sleep. 
We then address the mechanisms by which IL‑1 affects 
neurons and neurotransmitters involved in sleep regu‑
lation. Thus, the role of the serotonergic system in the 
regulation of sleep and as a mediator of IL‑1’s effects on 
sleep is reviewed. We conclude by proposing a hypoth‑
esis regarding the functional role of infection‑induced 
alterations in sleep which suggests that the precise man‑
ner in which sleep is altered during infection facilitates 
the generation of fever and so promotes recovery.
Sleep in health and disease
Sleep is necessary for health. Although the brain gives us 
signals that indicate when we have had insufficient sleep, 
data show that more and more of us are ignoring these 
signals and reducing the amount of sleep we obtain each 
night. The percentage of adults who sleep less than 6 h 
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Abstract | Good sleep is necessary for physical and mental health. For example, sleep loss 
impairs immune function, and sleep is altered during infection. Immune signalling molecules 
are present in the healthy brain, where they interact with neurochemical systems to 
contribute to the regulation of normal sleep. Animal studies have shown that interactions 
between immune signalling molecules (such as the cytokine interleukin 1) and brain 
neurochemical systems (such as the serotonin system) are amplified during infection, 
indicating that these interactions might underlie the changes in sleep that occur during 
infection. Why should the immune system cause us to sleep differently when we are sick? We 
propose that the alterations in sleep architecture during infection are exquisitely tailored to 
support the generation of fever, which in turn imparts survival value.
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Encephalitis lethargica
An infectious process and an 
associated inflammatory 
response involving the brain 
and characterized by 
pronounced somnolence. The 
first cases were described in 
1916 by the Viennese 
neurologist von economo. The 
pathology is typical of viral 
infections and is localized 
principally to the midbrain, the 
subthalamus and the 
hypothalamus. The causative 
agent has not been definitively 
determined.
Trypanosomiasis
A disease caused by the 
protozoan Trypanosoma brucei 
and transmitted by several 
species of the tsetse fly. When 
the brain and meninges 
become involved, usually in the 
second year of infection, a 
chronic progressive neurologic 
syndrome results. Complete 
loss of the timing of sleep, 
alterations in sleep 
architecture, and later apathy, 
stupor and coma characterize 
the syndrome.
Sleep fragmentation
interruption of sleep bouts by 
brief arousals such that the 
duration of the bout is reduced 
and transitions from one 
behavioural state to another 
occur more frequently.
per night is now greater than at any other time on record4. 
These survey data do not allow us to determine the extent 
to which the declining amounts of sleep are due to sleep 
disorders or to behavioural decisions, but it is clear that 
our current practice of sleeping less is largely driven by 
societal changes, including increased reliance on longer 
work hours and shift work, the trend for longer commute 
times, and increased accessibility to media of all sorts.
What are the consequences of sleep loss? historically, 
it was widely thought that the only consequence of night‑
time sleep loss was daytime sleepiness resulting in cogni‑
tive impairment. We now have compelling evidence that, 
in addition to cognitive impairment, sleep loss is asso‑
ciated with a wide range of detrimental consequences, 
with tremendous public‑health ramifications. For exam‑
ple, short periods of sleep loss at the time of vaccination 
reduce the vaccine’s effectiveness5,6. Sleep loss is associ‑
ated with increased obesity7,8 and with reduced levels of 
leptin and increased levels of ghrelin8,9, the combination 
of which increases appetite. Sleep loss is also associated 
with diabetes and impaired glucose tolerance in a dose‑
related manner: individuals that report sleeping less than 
6 h per night are ~1.7 times as likely, and those that report 
sleeping less than 5 h per night are ~2.5 times as likely, to 
have diabetes than individuals that obtain 7 h of sleep10. 
Cardiovascular disease and hypertension are also associ‑
ated with sleep loss: the risk of a fatal heart attack increases 
45% in individuals who chronically sleep 5 h per night 
or less11. Collectively, these examples demonstrate wide‑ 
ranging consequences of sleep loss on physical health. 
Obesity, diabetes and cardiovascular disease are pathologies 
that are characterized, in part, by inflammatory processes. 
The magnitude of the public‑health burden imposed by 
these and other diseases underscores the importance of 
relationships between sleep and immune function and our 
efforts to understand them.
Sleep is disturbed during disease. We have all experi‑
enced the feelings of lethargy and fatigue associated with 
being sick. Some infections induce dramatic alterations 
in sleep. For example, recent cases of an encephalitis 
lethargica‑like syndrome have been associated with 
streptococcal infections, during which severe sleep dis‑
ruption occurs12. In addition, there is an extensive body 
of literature which demonstrates that the sleep of indi‑
viduals infected with hIv is altered even before they 
show symptoms of AIDS13. Furthermore, infection with 
the parasite Trypanosoma brucei, the causative agent 
of human African trypanosomiasis (sleeping sickness), 
results in extreme fragmentation of sleep and a complete 
loss of the diurnal rhythms of sleep and wakefulness14,15. 
Although most people fortunately do not encounter 
these catastrophic infections, we have all suffered 
colds or ‘the flu’, and sleep is altered during these more 
common infections as well16,17.
Cytokines and sleep
Immune responses during infection include alterations 
in the concentrations and patterns of immune signal‑
ling molecules called cytokines. The list of cytokines 
and chemokines that have been studied in laboratory 
animals or human subjects and demonstrated to affect 
sleep is extensive and includes IL‑1α, IL‑1β, IL‑2, IL‑4, 
IL‑6, IL‑8, IL‑10, IL‑13, IL‑15, IL‑18, TNFα, TNFβ, 
interferon‑α (IFNα), IFN‑β, INF‑γ and macrophage 
inhibitory protein 1β (also known as CCL4). Of these 
substances only two, IL‑1β (hereafter referred to as 
IL‑1) and TNFα (hereafter referred to as TNF), have 
been studied extensively enough to state that they are 
involved in the regulation of physiological (that is, spon‑
taneous) sleep18–20. Evidence for a role for IL‑1 and TNF 
in the regulation of physiological sleep has been derived 
from electrophysiological, biochemical and molecular 
genetic studies.
Cytokines participate in the regulation of sleep. Although 
most cytokines were first discovered in the peripheral 
immune system, several cytokines and their receptors 
have now been shown to be present in the CNS21–23. The 
CNS detects activation of the peripheral immune system 
Timeline | A brief history of cytokines and sleep
400 BC 1892 ~1900 1909 1930 1960 1967 1971 1975 1978 1982 1983 1984 1985 1987 
 “Fatigue 
substances” 
are proposed 
to cause 
sleep117.
Aristotle writes Sleep 
and Waking and 
documents the basic 
human experience that 
fever is commonly 
associated with feelings 
of lethargy and fatigue.
(1909–1913) Early evidence for humoral 
regulation of sleep is obtained by the 
laboratories of Ishimori120 in Japan and 
Legendre and Piéron121 in France. Both groups 
demonstrate that transfer of cerebrospinal fluid 
obtained from sleep-deprived dogs induces 
deep and prolonged sleep in recipient animals.
Sleep-promoting Factor S is 
determined to be a 
low-molecular-mass fraction 
of goat cerebrospinal fluid 
that progressively increases 
in concentration during 48 h 
of sleep deprivation126.
(1930s–1950s) Neural 
theories proposed by von 
Economo, Hess, Moruzzi, 
Nauta and others 
overshadow humoral 
theories of sleep.
Factor S is 
extracted127.
Factor S is characterized 
and found to be muramyl 
peptide129,130, an immune 
adjuvant known to 
induce the production of 
interleukin 1.
(1960s–1970s) Studies once again 
begin to focus on humoral regulation 
of sleep. Several laboratories, notably 
those of Kornmüller122, Monnier123 
and Uchizono124, focus their research 
efforts on identifying endogenous 
sleep-promoting substances.
Pappenheimer and colleagues 
demonstrate that cerebrospinal 
fluid from sleep-deprived goats 
reduces locomotor activity and 
increases sleep in rats125.
Factor S is 
purified128.
Fontana reports 
that astrocytes 
produce an 
interleukin 1-like 
factor131.
Tigerstedt and 
Bergman118 and 
Bayliss and Starling119 
signal the birth of a 
discipline that would 
become known as 
endocrinology.
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through cytokine‑induced stimulation of the vagus 
nerve, through actions of circulating cytokines at the cir‑
cumventricular organs and through active transport of 
cytokines from the periphery into the CNS (reviewed in 
ReF. 3). however, cytokines are also synthesized de novo 
and released in the CNS by both neurons24–26 and glia23. 
Neurons that are immunoreactive for IL‑1 and TNF are 
located in brain regions that are implicated in the regula‑
tion of sleep–wake behaviour, notably the hypothalamus, 
the hippocampus and the brainstem24,27. Signalling recep‑
tors for both IL‑1 and TNF are also present in several 
brain areas, such as the choroid plexus, the hippo campus, 
the hypothalamus, the brainstem and the cortex, and are 
expressed in both neurons and astrocytes22,28,29.
IL‑1 and TNF increase non‑REM (NREM) sleep in 
several species (rat, mouse, monkey, cat, rabbit and sheep) 
irrespective of the route of administration18,20. NREM sleep 
that follows the administration of IL‑1 or TNF has some 
characteristics of physiological sleep in the sense that it 
remains episodic and is easily reversible when the animal 
is stimulated. however, IL‑1 generally causes fragmenta‑
tion of NREM sleep30. The magnitude and duration of 
IL‑1’s effects on NREM sleep depend on the dose30,31 and 
time31,32 of administration: very high doses are NREM‑
sleep suppressive31 and, in rodents, IL‑1 is more effec‑
tive in increasing NREM sleep when it is administered 
before the dark phase of the light–dark cycle31,32.
In accordance with the increase in NREM sleep 
that occurs after administration of IL‑1 or TNF, 
antagonizing either of these cytokine systems reduces 
spontaneous NREM sleep. For example, inactivating 
or interfering with the normal action of IL‑1 or TNF 
by means of antibodies, antagonists or soluble recep‑
tors reduces both spontaneous NREM sleep and the 
increase in NREM sleep that occurs after sleep depri‑
vation18,20. Preventing the cleavage of active IL‑1 from 
its inactive precursor also reduces spontaneous NREM 
sleep33. Furthermore, antagonizing these cytokine 
systems attenuates the increase in NREM sleep that 
follows excessive food intake or acute elevation of 
ambient temperature34, both of which are associated 
with enhanced production of either IL‑1 or TNF. 
Moreover, knockout mice that lack the type 1 IL‑1 
receptor, the type 1 TNF receptor or both35 spend less 
time in NREM sleep than control mice.
Administration of cytokines has been repeatedly 
shown to suppress REM sleep18, but antagonizing 
endogenous cytokines in healthy animals with receptor 
antagonists, soluble receptors or antibodies either has 
no effect on REM sleep or only slightly reduces it33,36,37. 
These observations suggest that cytokines modulate 
REM sleep during pathological conditions but do not 
contribute to the regulation of normal, physiological 
REM sleep. Moreover, recent demonstrations that altera‑
tions in REM sleep in mice lacking both IL‑1 receptor 1 
and TNF receptor 1 occur independently of changes in 
NREM sleep suggest that these cytokines influence REM 
sleep through mechanisms that differ from those that are 
involved in NREM‑sleep regulation35.
Finally, the fact that diurnal rhythms of IL‑1 and TNF 
levels vary with the sleep–wake cycle provides further evi‑
dence for the involvement of IL‑1 and TNF in physiologi‑
cal sleep regulation18,20. In rats, IL‑1 and TNF mRNA and 
protein levels in the brain exhibit a diurnal rhythm with 
peaks that occur at light onset38; the light period in these 
rodents is the time when NREM sleep propensity is at a 
maximum. In humans, IL‑1 plasma levels are highest at 
the onset of sleep39, and in cats cerebrospinal fluid IL‑1 
levels vary with the sleep–wake cycle40.
Cytokines mediate changes in sleep induced by infection. 
The data briefly reviewed above show that at least two 
pro‑inflammatory cytokines are involved in regulating 
spontaneous, physiological NREM sleep. The question 
that then arises is whether these cytokines also medi‑
ate infection‑induced alterations in sleep. Numerous 
systematic preclinical studies have demonstrated the 
extent to which infection alters sleep (reviewed in 
ReFS 18,20,41). Although the precise alterations depend 
on the pathogen (bacteria, viruses, fungi or para‑
sites), the host and the route of infection, at some time 
during the course of most infections there is an increase 
in the amount of time spent in NREM sleep and a 
decrease in the amount of REM sleep.
Models in which replicating pathogens are used to 
make animals sick are the most clinically relevant, but 
these types of studies are difficult to perform and inter‑
pret because the disease state develops over periods of 
days to weeks and the responsiveness to the infection 
can differ dramatically between animals. however, the 
changes induced in sleep by infectious agents are due 
to immune responses to biologically active structural 
components of the pathogen. Indeed, administration of 
such biologically active structural components results 
in changes in sleep that mimic those observed during 
infection with replicating pathogens. For this reason, 
most mechanistic studies of infection‑induced altera‑
tions in sleep have used these structural components 
to induce the many facets of immune responses in 
the absence of replicating pathogens. The most com‑
monly used are bacterial cell wall components such as 
Timeline | A brief history of cytokines and sleep
400 BC 1892 ~1900 1909 1930 1960 1967 1971 1975 1978 1982 1983 1984 1985 1987 
Two full-length papers demonstrate that 
central administration of interleukin 1 into 
rabbits or rats increases the amount of time 
spent in non-rapid eye movement sleep and 
alters the amplitude of the electroencepha-
logram waveform in the slow frequency 
bands133,134.
(1985 onwards) Much is learnt 
about the mechanisms and sites 
of action whereby interleukin 1 
and other cytokines regulate 
sleep18. 
An abstract presented at 
the annual meeting of 
the Federation of 
American Societies for 
Experimental Biology132 
reports sleep-inducing 
effects of interleukin 1.
Tumour necrosis factor 
is first reported to 
increase non-rapid eye 
movement sleep of 
rabbits135.
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Lipid A
The innermost, hydrophobic, 
lipid component of 
lipopolysaccharide. lipid A 
anchors the lipopolysaccharide 
to the outer membrane of the 
Gram-negative bacterial cell 
wall.
Lipopolysaccharide
A component (also known as 
endotoxin) of the outer wall of 
Gram-negative bacterial cell 
walls. it is composed of a lipid 
and polysaccharides joined by 
covalent bonds. it elicits strong 
immune responses through 
signalling pathways coupled to 
Toll-like receptor 4.
Muramyl dipeptide
The synthetic analogue of 
muramyl peptides, the 
monomeric building blocks of 
bacterial cell wall 
peptidoglycan. muramyl 
peptides are released by 
mammalian macrophages 
during the digestion of 
bacterial cell walls.
lipid A, lipopolysaccharide and muramyl peptide (or the 
synthetic muramyl dipeptide). These bacterial cell 
wall components induce strong antigenic responses 
such as upregulation of pro‑inflammatory cytokines, 
including IL‑1 and TNF42–44. When these bacterial 
cell wall components are administered to rabbits, rats, 
mice or humans (BOX 1), NREM sleep is increased and 
fragmented and REM sleep is suppressed45.
Of importance to this discussion, the effects of bac‑
terial cell wall components on sleep are attenuated or 
blocked if cytokine systems are antagonized. For exam‑
ple, increases in NREM sleep after lipopolysaccharide 
or muramyl dipeptide administration are blocked if the 
IL‑1 system is antagonized33,46. These data suggest that 
infection‑induced alterations in sleep are mediated by 
cytokines such as IL‑1 and TNF. They also show that 
administration of cytokines or pathogen components 
can serve as a model of infection‑induced alterations in 
sleep. The advantages of such models are that responses 
occur on a timescale of hours rather than days or weeks, 
that many facets of immune and behavioural responses 
to infection are elicited, and that it is relatively easy to 
titrate the magnitude of the desired response.
Serotonin and sleep
Sleep, like any behaviour, is regulated in the brain by 
multiple overlapping neuroanatomic circuits and related 
neuro chemical systems. IL‑1 and TNF interact with sev‑
eral of these systems, including the serotonin (also known 
as 5‑hydroxytryptamine (5‑hT)) system47. The 5‑hT 
system is one of the most investigated transmitter systems 
with respect to the regulation of sleep. In this section of 
the Review we briefly summarize the extensive body of lit‑
erature that has demonstrated a role for the 5‑hT system 
in regulating arousal states. Basic knowledge of 5‑hT’s 
complex role in sleep regulation is necessary before one 
can fully understand how interactions between the IL‑1 
and 5‑hT systems contribute to the regulation of sleep.
Observations in 1955 (ReF. 48) by Brodie and col‑
leagues that brain 5‑hT depletion by reserpine induces 
sedation prompted investigation of the role of 5‑hT in 
the regulation of sleep–wake behaviour. 5‑hT has since 
been shown to regulate multiple physiological processes 
and behaviours, including vigilance states, mood, food 
intake, thermoregulation, locomotion and sexual behav‑
iour49. The importance of the 5‑hT system’s role in sleep 
regulation is supported by both experimental data and 
clinical observations: pharmacological manipulations 
that affect the 5‑hT system by altering neurotransmit‑
ter synthesis, release, binding or re‑uptake and metabo‑
lism result in profound alterations in sleep50. Sleep is also 
altered during clinical conditions such as depression, in 
which the functionality of the 5‑hT system is thought 
to be chronically altered51.
5-HT promotes arousal but is necessary for NREM 
sleep. The exact role of 5‑hT in sleep regulation has 
been subject to debate50,52. Data obtained in the 1960s 
and early 1970s suggested that the 5‑hT system is nec‑
essary for NREM sleep: the destruction of raphe nuclei 
 Box 1 | Sleep and immunity in human volunteers
There are some differences between laboratory animals and human subjects with respect to sleep–immune interactions. 
Most studies that use laboratory animals focus on the effects of host-defence activation on sleep and often include as 
outcome measures changes in immunomodulators in the brain. By contrast, the vast majority of studies that use human 
volunteers determine the effects of sleep loss on multiple facets of immunity, and immune-related outcome measures are 
almost always restricted to measures that can be obtained from whole blood, serum or plasma. The negative impact of 
sleep loss on public health is now recognized for pathologies that involve inflammatory processes, underscoring the 
importance of sleep to a healthy immune system.
It would be unethical to experimentally infect humans, but there are numerous clinical studies that describe the impact 
of HIV or trypanosome infection on sleep, all of which report that sleep is indeed altered. Healthy human volunteers 
under careful medical supervision have been subjected to host-defence activation by purified endotoxin101, an immune 
challenge in which there are no replicating pathogens. These studies show that humans are more sensitive to endotoxin 
than are laboratory animals; in humans, slow-wave sleep (the equivalent of non-rapid eye movement sleep in animals) is 
increased across the night by very low, subpyrogenic doses of endotoxin (less than one-thousandth of the 
per-bodyweight dose that elicits sleep responses in rats)102. As the endotoxin dose increases there are transient increases 
in slow-wave sleep, lasting approximately 1 h103. With even higher doses of endotoxin a much stronger host-defence 
response develops and, as in laboratory animals, sleep is severely disrupted102. This is probably due, in part, to increased 
activity of the hypothalamic-pituitary-adrenal axis, which induces wakefulness and promotes arousal104,105.
As mentioned above, in contrast to the few reports of the effect of host-defence activation by endotoxin in humans, 
there have been numerous systematic studies in which human volunteers have been deprived of sleep and effects on 
immunity determined. The first study of the effects of sleep loss on immunity in humans seems to be that of Palmblad 
et al.106. They demonstrated that 48 h of sleep deprivation reduced phytohaemagglutinin-induced DNA synthesis in 
lymphocytes, an effect that persisted for 5 days. This study was followed by more than 50 other studies that showed 
effects of sleep deprivation on the human immune system. By way of example, 64 h sleep deprivation is associated with 
alterations in many aspects of immunity, including leukocytosis, increased natural killer cell activity and increased counts 
of white blood cells, granulocytes and monocytes107. According to recent reports, as little as 4 h of sleep loss in a 
controlled laboratory setting increases the production of interleukin 6 and tumour necrosis factor by monocytes — an 
effect that, bioinformatic analyses suggest, is mediated by the nuclear factor-κB inflammatory signalling pathway108. The 
number and scope of studies of human sleep loss and immunity exceed that which can be summarized in this Review, and 
so for recent comprehensive reviews see ReFS 19,109.
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Sleep factors
(IL-1)
Sleep-promoting
neurons
(GABA and galanin)
Wake-promoting
neurons
(ACh and GABA)
Wake-promoting neurons
LC
(NA)
VTA
(DA)
LDT–PPT
W-REM on
(ACh)
TMN
(histamine)
PeF
(hypocretin)
Dorsal raphe nucleus
Serotonergic cell bodies
(5-HT)
Anterior hypothalamus and 
preoptic area/basal forebrain 
Brainstem and posterolateral hypothalamus 
Nature Reviews | Neuroscience
Direct, early effect
↑ Wakefulness 
Indirect, delayed effect 
↑ NREM sleep
(which contain the cell bodies of 5‑hT neurons) or the 
depletion of brain 5‑hT by administration of the 5‑hT 
synthesis inhibitor p‑chlorophenylalanine (PCPA) 
induces insomnia that is selectively reversed by the 
5‑hT precursor 5‑hydroxytryptophan (5‑hTP) 50,52. 
however, data obtained from the mid 1970s onwards 
suggested that 5‑hT promotes wakefulness and sup‑
presses NREM sleep. For instance, experimental 
manipulations that increase the release and synaptic 
availability of 5‑hT, such as electrical stimulation of 
the dorsal raphe nuclei (DRN), enhance wakefulness, 
whereas DRN inactivation enhances sleep53. In support 
of a wake‑promoting role for 5‑hT, a body of evidence 
has shown that the firing rates of serotonergic raphe 
neurons54–57 and 5‑hT release58–61 are state‑dependent: 
they peak during wakefulness and decrease during 
NREM sleep, and serotonergic cells become silent 
during REM sleep. In agreement with the interpreta‑
tion that 5‑hT is a wake‑inducing substance, blockade 
of 5‑hT2 receptors increases NREM sleep in rats and 
humans62. (A more detailed discussion of the role of 
5‑hT receptor subtypes in NREM‑sleep regulation 
is beyond the scope of this Review.) 5‑hT enhances 
wakefulness because serotonergic neurons in the DRN 
(together with other wake‑promoting neurons, such as 
noradrenergic neurons in the brainstem locus coeru‑
leus or hypocretinergic/orexinergic neurons in the 
hypothalamus) inhibit sleep‑promoting neurons in 
the preoptic area, the anterior hypothalamus and the 
adjacent basal forebrain50,63 (FiG. 1). Noradrenergic and 
hypocretinergic/orexinergic wake‑promoting neurons 
also stimulate each other’s activity64.
An attempt to integrate and reconcile these appar‑
ently contradictory data led to the hypothesis that 
5‑hT promotes wakefulness through direct actions 
and also stimulates the synthesis and/or release of sleep‑
promoting factors52. Data now support this dual‑role 
hypothesis for the involvement of 5‑hT in the regula‑
tion of arousal states. The purported sleep‑promoting 
factors induced by 5‑hT drive sleep by inhibiting wake‑
promoting neurons and stimulating sleep‑promoting 
neurons (FiG. 1). Data obtained from rats and mice65–67 
suggest that the role of 5‑hT in the regulation of arousal 
states depends on the degree to which the 5‑hT system 
is activated, the timing of the activation and the time 
that has passed since the activation (FiG. 1). When 5‑hT 
release is enhanced in rats and mice through the admin‑
istration of 5‑hTP, the initial response is an increase in 
wakefulness and a reduction in NREM sleep65–67. This 
increase is fast, indicating that it is probably a direct 
effect of 5‑hT. however, low doses of 5‑hTP might 
not activate the 5‑hT system sufficiently to stimulate 
sleep‑inducing factors, a process that requires time. 
Following administration of higher physiological doses 
of 5‑hTP, an increase in NREM sleep is apparent, after 
a delay, in both rats and mice65–67. This delayed increase 
in NREM sleep always occurs during the dark phase of 
the light–dark cycle, irrespective of the timing of 5‑hTP 
administration65–67. Findings that 5‑hTP administration 
increases the NREM sleep of rodents only during the 
dark phase suggest a fundamental property of the 5‑hT 
system: the precise effects of serotonergic activation on 
sleep–wake behaviour depend not only on the extent but 
also on the timing of activation.
The data summarized above are in agreement with 
observations that acute administration in cats and rats of 
selective 5‑hT re‑uptake inhibitors first increases wake‑
fulness and then increases NREM sleep50. The first stud‑
ies of the relationship between 5‑hT and sleep, carried 
Figure 1 | serotonin initially increases wakefulness and subsequently increases 
non-rapid eye movement sleep. Serotonergic neurons of the dorsal raphe nucleus, as 
well as other wake-promoting neurons located in the brainstem and the posterolateral 
hypothalamus, inhibit sleep-promoting neurons in the anterior hypothalamus, the 
preoptic area and the adjacent basal forebrain63,64. In turn, these rostral sleep-promoting 
neurons inhibit wake-promoting neurons in the brainstem and the posterolateral 
hypothalamus63,64. Serotonin (also known as 5-hydroxytryptamine (5-HT)) also induces 
the synthesis and/or release of sleep-promoting factors, which subsequently inhibit 
rostral wake-promoting neurons and activate rostral sleep-promoting neurons of the 
hypothalamus and basal forebrain. Interleukin 1 (IL-1) may be one of the 5-HT-induced 
sleep factors because serotonergic activation induces IL-1 mRNA expression in the 
hypothalamus89 and IL-1 inhibits wake-promoting neurons in the hypothalamic preoptic 
area/basal forebrain82. IL-1 also inhibits wake-promoting serotonergic neurons in the 
dorsal raphe nucleus74,75. The schema is not intended to depict all interrelationships 
between the neuroanatomic regions and neurochemical systems involved in sleep 
regulation; rather, it is intended to illustrate the potential mechanisms by which 5-HT 
promotes wakefulness per se and at the same time stimulates the synthesis and/or 
release of sleep-promoting factors that then drive the sleep that naturally follows 
wakefulness52. ACh, acetylcholine; DA, dopamine; GABA, γ-aminobutyric acid; LC, locus 
coeruleus; LDT–PPT, laterodorsal and pedunculopontine tegmental nuclei; NA, 
noradrenaline; NREM, non-rapid eye movement; PeF, perifornical region; TMN, 
tuberomammillary nucleus; VTA, ventral tegmental area; W-REM on, neurons that are 
active during both wakefulness and rapid eye movement sleep.
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out in the 1960s, were based on behavioural observa‑
tions and did not include polygraphically defined 
determinations of vigilance states. Nevertheless, these 
studies reported biphasic responses to 5‑hT administra‑
tion in which behavioural ‘activation’ was followed by 
‘depression’ (ReF. 50).
Serotonin suppresses REM sleep. Serotonergic neurons 
in the raphe nuclei, like noradrenergic neurons in the 
locus coeruleus, are considered to be part of the sys‑
tems that gate REM sleep by inhibiting the neurons 
that promote it68,69. In this view, suppressed seroton‑
ergic activity is permissive of REM‑sleep generation, 
which is consistent with observations that pharmaco‑
logical inhibition of the 5‑hT system enhances REM 
sleep whereas increases in synaptic 5‑hT availability 
inhibit it50. Accordingly, in rats and mice activation of 
the 5‑hT system by administration of 5‑hTP inhib‑
its REM sleep, regardless of the dose and timing of 
administration65–67. The observation that mice that 
lack 5‑hT1A or 5‑hT1B receptor subtypes spend more 
time in REM sleep than control mice suggests that 
these receptor subtypes mediate the inhibitory effects 
of 5‑hT on REM sleep70. Such a conclusion, supported 
by responses to pharmacological blockade of the same 
receptor subtypes70, of course does not rule out the pos‑
sibility that 5‑hT can also inhibit REM sleep by bind‑
ing to other 5‑hT receptor subtypes. At variance with 
the ‘REM‑off ’ role of 5‑hT, observations that admin‑
istration of a 5‑hT7 receptor antagonist inhibits REM 
sleep in rats71 and that 5‑hT7 receptor‑knockout mice 
spend less time in this sleep phase72 suggest that 5‑hT 
might have a facilitatory (or permissive) role in REM‑
sleep regulation through this specific receptor subtype. 
The role of 5‑hT2A or 5‑hT2C receptors in REM‑sleep 
regulation is more complex70.
Interactions between Il‑1 and 5‑HT
Evidence consistently demonstrates that IL‑1 has a role 
in regulating physiological NREM sleep by acting, in 
part, through well‑defined neuromodulatory systems. 
For example, IL‑1 stimulates the synthesis and/or 
release of growth hormone‑releasing hormone, prosta‑
glandin D2, adenosine and nitric oxide. Each of these 
substances is implicated in regulating or modulating 
NREM sleep, and antagonizing these systems attenu‑
ates or blocks IL‑1‑induced increases in NREM sleep. 
For an extensive review of the role of neuromodula‑
tory systems in mediating cytokine effects on sleep, 
see ReF. 73.
In addition to acting on these neuromodulatory sys‑
tems, IL‑1 acts directly on specific brain circuits and 
interacts with several neurotransmitters that have been 
implicated in regulating sleep. Thus, IL‑1’s effects on 
NREM sleep could be mediated by actions on several 
neurotransmitter systems, although systematic investi‑
gations of the interactions between IL‑1 and neurotrans‑
mitter systems that are relevant to the regulation of sleep 
remain to be conducted (BOX 2). here, we focus on the 
interactions between IL‑1 and the 5‑hT system because 
 Box 2 | effects of interleukin 1 on neurotransmitters involved in sleep regulation
This Review focuses on interactions between interleukin 1 (IL-1) and the serotonergic system and, where relevant, on 
interactions between IL-1 and the GABA (γ-aminobutyric acid)-ergic system. There are also some published reports  
of interactions between IL-1 and other neurotransmitter systems that are relevant to sleep regulation, and here we 
present a brief overview.
Acetylcholine (Ach)
Pontomesencephalic cholinergic neurons have a key role in rapid eye movement (REM) sleep generation and, together 
with basal forebrain cholinergic neurons, in cortical desynchronization and activation64,68. IL-1 inhibits ACh release in the 
hippocampus in vivo110, inhibits ACh synthesis in vitro in cultured pituitary cells111 and increases acetylcholinesterase 
activity and mRNA expression in neuron–glia co-cultures and in vivo in the rat cortex112. Suppression of REM sleep by IL-1 
(ReF. 18) may be mediated by inhibition of pontomesencephalic cholinergic neurons.
Glutamate
Glutamate is widely used in the CNS. For instance, it is released by the neurons that project from the brainstem reticular 
formation, which is part of the ascending arousal system64. Many anaesthetics attenuate glutamate-mediated 
neurotransmission64. Interactions between IL-1 and glutamatergic neurotransmission have been investigated at length 
because of the involvement of glutamate excitotoxicity in neuron loss during stroke or chronic neurodegenerative 
disease113. Evidence suggests that IL-1 can potentiate or inhibit the effects of glutamate22,113. For instance, IL-1 decreases 
evoked glutamatergic excitatory responses in hippocampal CA1 pyramidal neurons81.
Adenosine
Adenosine, which is a by-product of energy metabolism, promotes sleep by inhibiting cholinergic and non-cholinergic 
wake-promoting neurons in the basal forebrain114. Because IL-1 stimulates adenosine production115,116, this effect can 
further contribute to IL-1-induced increases in non-REM sleep. Moreover, IL-1-induced inhibition of glutamatergic 
responses (at least in the hippocampus) is mediated by adenosine81.
Monoamines
Brainstem noradrenergic neurons of the locus coeruleus, dopaminergic neurons of the substantia nigra and ventral 
tegmental area and histaminergic neurons in the posterior hypothalamus are all wake-promoting64. IL-1 activates 
these aminergic neurons and thereby enhances monoamine release in different brain areas47. Owing to their role in 
promoting wakefulness, IL-1-induced activation of aminergic neurons might counteract the increase in NREM sleep 
and thus maintain homeostasis.
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these are the interactions for which the most data have 
accumulated during the past 10 years. We review the evi‑
dence that IL‑1 enhances NREM sleep in part through 
opposing but complementary actions on the 5‑hT sys‑
tem in two distinct neuroanatomical regions, namely the 
DRN and the preoptic area of the hypothalamus, and 
the adjacent preoptic area and basal forebrain (POA/
BF), which receives serotonergic innervation from 
the DRN. We show that IL‑1 has inhibitory actions 
on the cell bodies of the wake‑promoting DRN 5‑hT 
system and increases 5‑hT release from axon terminals 
in the POA/BF.
IL-1 actions in the DRN. IL‑1 microinjection into the 
DRN of rats increases their NREM sleep74. In a brain‑
stem slice preparation, bath application of IL‑1 reduces 
the firing rates of DRN wake‑promoting serotonergic 
neurons74,75 by enhancing GABA (γ‑aminobutyric 
acid)‑induced inhibitory postsynaptic potentials75 (FiG. 2a). 
Thus, IL‑1 potentiates the physiological GABAergic 
inhibition that shapes the state‑dependent discharge 
of DRN serotonergic neurons. IL‑1 potentiates GABA 
signalling through multiple mechanisms: it recruits 
GABAA receptors to the cell surface76; it increases Cl– 
uptake by acting on GABAA receptors77; and it induces 
a delayed potentiation of the GABA‑elicited Cl– cur‑
rent, an effect that is suppressed by the IL‑1 receptor 
antagonist76. The observation that IL‑1 potentiates the 
effects of GABA in the DRN is in agreement with data 
which demonstrate that IL‑1 enhances GABA‑induced 
hyperpolarization and inhibition in other brain regions 
where IL‑1 acts both pre‑ and postsynaptically: IL‑1 
increases GABA release in anterior hypothalamic/pre‑
optic area slice preparations78 and in brain explants79 
and enhances GABAergic inhibitory postsynaptic 
potentials in hippocampal neurons80,81.
Figure 2 | interleukin 1 and serotonin interact at multiple sites in the brain to regulate non-rapid eye 
movement sleep. A schematic representation of interactions in the brain among interleukin 1 (IL-1), serotonin (also 
known as 5-hydroxytryptamine (5-HT)) and γ-aminobutyric acid (GABA) that are relevant for the regulation of 
non-rapid eye movement (NREM) sleep. In the dorsal raphe nuclei (DRN), where IL-1 microinjections promote NREM 
sleep74, IL-1 reduces the firing rate of wake-active serotonergic neurons by enhancing the inhibitory effects of 
GABA75 (a). In the hypothalamic preoptic area/basal forebrain region (POA/BF), IL-1 stimulates 5-HT release from 
axon terminals59 (b). 5-HT, in turn, inhibits cholinergic neurons involved in cortical activation86 (c) and stimulates the 
synthesis of IL-1 (ReF. 89) (d), which inhibits wake-promoting neurons (e) and activates a subset of sleep-promoting 
neurons in the POA/BF82. IL-1 in the POA/BF is under potent inhibitory homeostatic control by corticosteroids92 (f) 
released into the blood by the adrenal cortex. Corticosteroid levels depend on the activity of the hypothalamic- 
pituitary-adrenal axis92, which is stimulated by activation of the 5-HT system89 (g). ACh, acetylcholine; ACTH, adreno-
corticotropic hormone; CRH, corticotropin-releasing hormone; IPSP, inhibitory postsynaptic potential; PVN, 
paraventricular nucleus of the hypothalamus.
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Acute-phase response
The reaction that develops in 
response to an injury or 
infection. it is mediated by 
pro-inflammatory cytokines 
(such as il-1) and is 
characterized by a local 
response (inflammation) and a 
systemic component, which 
includes the production of 
acute-phase proteins by 
hepatocytes, leukocytosis, 
fever and profound changes in 
lipid, protein and carbohydrate 
metabolism.
Sickness behaviour
The constellation of symptoms 
(decreased food intake, 
depressed activity, loss of 
interest in usual activities, 
disappearance of 
self-maintenance behaviours 
and altered sleep) that 
accompany responses to 
infection.
IL-1 effects in the POA/BF. In the POA/BF, a brain 
area that is crucial for sleep regulation63,64, IL‑1 directly 
inhibits wake‑promoting neurons (FiG. 2e) and stimu‑
lates a subset of sleep‑promoting neurons82. IL‑1 also 
increases the number of c‑FOS‑immunoreactive 
neurons in the POA/BF83. The number of these c‑FOS‑
immunoreactive neurons positively correlates with the 
amount of NREM sleep during the 2 h before sacrifice, 
suggesting that the stained neurons were active during 
this sleep phase and thus might be sleep‑active neu‑
rons. In addition, IL‑1 stimulates 5‑hT release from 
axon terminals in the POA59 (FiG. 2b). IL‑1 induces 
a tonic increase in 5‑hT release but does not alter 
the state‑dependent pattern of release — that is, the 
phasic increases in 5‑hT release during wakefulness 
and the decreases during sleep are superimposed on 
the tonic IL‑1‑induced increase in 5‑hT release59. The 
IL‑1‑induced enhancement of 5‑hT release from axon 
terminals can result from local actions that are inde‑
pendent of the effects on serotonergic cell bodies in the 
DRN, because release from axon terminals is elicited by 
application of IL‑1 directly into the hypothalamus84. The 
POA/BF is the only brain area where increasing seroton‑
ergic activity by administering 5‑hTP restores physio‑
logical sleep in cats that have been made insomniac 
by PCPA administration85. 5‑hT in the POA/BF might 
be essential for NREM sleep, because it hyperpolarizes 
and inhibits the cholinergic neurons that are respon‑
sible for cortical activation86 (FiG. 2c). The results of 
these studies suggest that IL‑1 stimulates NREM sleep 
in part by enhancing axonal 5‑hT release in the POA/
BF, where IL‑1 and 5‑hT inhibit wake‑promoting 
neurons. 5‑hT is essential for the effects of IL‑1 on 
NREM sleep to fully manifest, because depletion 
of brain 5‑hT by PCPA administration87 or block‑
ade of 5‑hT2 receptors88 transiently interferes with 
IL‑1‑induced increases in NREM sleep.
Not only does IL‑1 induce 5‑hT release and inhibit 
wake‑promoting neurons in the hypothalamus, but 
reciprocal interactions between the 5‑hT system and 
the IL‑1 system are also of importance. Increasing 
serotonergic activation with 5‑hTP induces IL‑1 
mRNA transcription in the hypothalamus89 (FiG. 2d) 
during periods when NREM sleep is enhanced by the 
same treatment65. There is specificity to this effect as 
5‑hTP does not alter IL‑1 mRNA in the hippocampus 
or brainstem89. The 5‑hTP‑induced increase in IL‑1 
mRNA may be part of a self‑sustaining regulatory 
loop, because IL‑1 induces its own synthesis90,91. As 
a consequence, IL‑1 can amplify the 5‑hTP‑induced 
increase in IL‑1 concentrations in the POA/BF, thus 
potentiating the inhibition of wake‑promoting neurons 
in this region82 (FiG. 2e). Finally, IL‑1 mRNA and pro‑
tein are under potent homeostatic inhibitory control by 
the hypothalamic‑pituitary‑adrenal axis92 (FiG. 2f), the 
activity of which is increased by the activation of 
the 5‑hT system89 (FiG. 2g).
Collectively, the results of the studies reviewed sug‑
gest that the IL‑1 and 5‑hT systems engage in reciprocal 
interactions that contribute to the regulation of NREM 
sleep. In the POA/BF IL‑1 enhances axonal 5‑hT 
release and 5‑hT stimulates the synthesis of IL‑1, which 
inhibits wake‑promoting neurons. IL‑1 also inhibits 
wake‑active serotonergic cell bodies in the DRN. Thus, 
IL‑1 exerts opposite effects on serotonergic cell bod‑
ies and axon terminals. These effects complement each 
other and they both contribute to the same functional 
outcome: the enhancement of NREM sleep.
Why is sleep altered during sickness?
Sleep is clearly adaptive and much effort has been 
directed at determining its functions1,2,93,94. As we have 
reviewed, sleep is altered during infection. Infection 
increases the concentrations of cytokines, including IL‑1, 
and the release of neurotransmitters, including 5‑hT, in 
the brain, and interactions between IL‑1 and 5‑hT con‑
tribute to the regulation of sleep. We are beginning to 
understand how infection induces these changes, but 
it remains unknown why sleep is altered during sick‑
ness. We propose that altered sleep during infection, as 
a component of the acute-phase response and sickness 
behaviour, promotes recovery.
Is there any evidence to support the hypothesis 
that altered sleep during infection is a determinant of 
clinical outcome? Although it did not directly test this 
hypothesis, at least one study suggests that this might 
indeed be the case. Toth and colleagues95 retrospec‑
tively analysed data derived from long‑term studies 
of bacterial or fungal infection‑induced alterations 
in sleep in rabbits. The authors calculated for each 
animal a cumulative sleep‑quality score that reflected 
both the duration and the intensity of NREM sleep. 
This approach allowed stratification of the outcome 
on the basis of whether the animals had high or low 
sleep‑quality scores (good sleep or poor sleep, respec‑
tively) during the course of the infection. These cumu‑
lative sleep‑quality scores were then correlated with 
the infective dose of the pathogen, multiple clinical 
parameters and the outcome. Analyses revealed that 
the infective dose of the pathogen differed between 
animals, and animals that received a higher patho‑
gen dose generally had low cumulative sleep‑quality 
scores. This suggests that the sicker the animal, the 
more disrupted its sleep. however, and of importance 
to this discussion, there were individual differences in 
the fates of animals that received the same infective 
dose: animals that survived had higher sleep‑quality 
scores than animals that died. Although — as with any 
study that reports associations — this study did not 
demonstrate causality, and although it has yet to be 
repeated, these data are consistent with the hypoth‑
esis that dynamic changes in sleep during infection aid 
recovery.
how might infection‑induced alterations in sleep 
promote recovery? We propose that they facilitate 
the generation of fever. In this view it is fever that 
imparts survival value, and fever could not develop 
during infection if sleep architecture was not altered. 
This hypothesis is based on two extensive bodies of 
literature, one describing links between sleep and 
thermo regulation96 and the other indicating that fever 
is adaptive97.
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The regulation of body temperature is coupled to 
sleep96: superimposed on the circadian rhythm of body 
and brain temperature are arousal state‑dependent tem‑
perature changes (FiG. 3a). For example, brain and body 
temperature decrease during NREM sleep; the longer 
and more consolidated the NREM‑sleep episode, the 
greater the decrease in brain or body temperature, until 
the regulated asymptote is reached. By contrast, brain 
temperature increases rapidly during REM sleep96,98 
(FiG. 3a). In addition, thermoregulation is dependent on 
the sleep–wake state; for example, shivering does not 
occur during REM sleep96,99.
vertebrates and invertebrates develop fever in 
response to administration of pyrogens (fever inducers) 
or infection with pathogens. Data demonstrate increased 
survival when the host develops a moderate fever dur‑
ing bacterial or viral infections97. The survival value of 
fever to the host organism is conferred primarily by two 
mechanisms: facets of immune responses are potentiated 
at elevated body temperature, and the host environment 
is directly altered such that conditions for replication of 
the pathogen become less optimal97,100 (FiG. 4).
however, fever is energetically demanding: metabo‑
lism must be increased to raise and then maintain body 
temperature. It has been estimated that the mean increase 
in metabolism is 13% for every 1°C increase in body 
temperature100. Increasing the amount of time spent 
in NREM sleep reduces the energy expenditure that is 
associated with competing activities, such as locomotion. 
But the changes in sleep architecture that occur during 
infection (suppressed REM sleep and increased but more 
fragmented NREM sleep) might have additional, fever‑
promoting benefits: shivering is crucial to the generation 
of fever but does not occur during REM sleep96. Perhaps 
for this reason REM sleep is eliminated during the early 
stages of fever (FiG. 3b). Furthermore, thermoregulatory 
mechanisms that reduce heat loss complement those 
involved in heat production (shivering) in the effort to 
increase body temperature. As heat dissipation normally 
occurs during NREM sleep, the fragmented nature of 
NREM sleep during the febrile response (FiG. 3b) may be 
viewed as a mechanism to reduce heat loss.
Data demonstrate that fever is adaptive and has 
evolved to increase survival in response to infection. 
Figure 3 | sleep architecture is altered during fever. The relationship between fever and changes in sleep 
architecture is apparent when interleukin 1 (IL-1) is administered to rats. a | A representative hypnogram d picting 
sleep–wake cycles of a male Sprague–Dawley rat demonstrates arousal state-dependent changes in brain 
temperature. Shown is a record of sleep–wake states (green line) and brain temperature (red line) for consecutive 12 
s epochs recorded for 12 h after intracerebroventricular injection of vehicle. The injection was given at the 
beginning of the dark portion of the light–dark cycle. The expanded inset shows the arousal state-dependent 
changes in brain temperature that occur under normal conditions in a freely behaving rat. Brain temperature 
declines before entry into and during non-rapid eye movement (NREM) sleep, whereas it increases at the onset of 
and during REM sleep. Increases in brain temperature that are associated with wakefulness (wake) are of greater 
magnitude than those that occur during REM sleep. b | After intracerebroventricular injection of 5.0 ng IL-1 into 
the same rat as in part a, NREM sleep is fragmented, REM sleep is abolished (green line) and fever ensues (red line). 
The expanded inset shows the extent to which NREM sleep is fragmented during fever. This inset depicts the 
effects of IL-1 on sleep during the third post-injection hour, the same period presented in the expanded inset of 
part a. In this animal, the effects of IL-1 on NREM sleep and REM sleep are apparent for almost 6 h. Once 
NREM–REM sleep cycles reappear, arousal state-dependent changes become apparent and brain temperature 
subsides to control values.
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Although it is unlikely that sleep has evolved solely to 
support the generation of fever during infection, the 
alterations in sleep in response to microbial pathogens 
are exquisitely designed to fulfil this role: the increase in 
NREM sleep conserves energy; the suppression of REM 
sleep allows shivering and, therefore, the production of 
fever; and the fragmentation of NREM sleep reduces 
heat loss.
Conclusions and future directions
Sleep is necessary for health as its loss or restriction 
is associated with multiple detrimental consequences. 
Although the interactions with neurotransmitters and 
neuromodulators through which cytokines enhance 
NREM sleep have been investigated at length, direct 
actions of cytokines on neurons in brain regions 
involved in the regulation of this sleep phase have 
only recently been determined. At present we know 
little about the mechanisms by which cytokines 
inhibit REM sleep. Investigating these mechanisms is 
important because REM sleep is disrupted in many 
pathologies that involve altered cytokine concentra‑
tions. For example, disturbed REM sleep and cytokine 
dysregulation are characteristic of major depression3. 
In addition to elucidating the mechanisms by which 
cytokines contribute to the regulation of the amount, 
pattern and distribution of sleep, crucial functional 
questions also wait to be answered. More systematic 
studies are required before we can understand the 
nature of cytokine involvement in altered sleep dur‑
ing sickness. Also of importance is the question of the 
extent to which alterations in sleep during sickness 
contribute to clinical outcome. Do alterations in sleep 
during infection contribute to survival as we propose 
and as is suggested by correlations between sleep qual‑
ity and survival of infected rabbits95? Would recovery 
be facilitated if patients in hospitals were able to sleep 
better? Further investigation is required to better assess 
the mechanistic and functional relationships between 
sleep and morbidity and mortality, and to determine 
whether altered sleep promotes recovery.
Figure 4 | Proposed principles by which changes in sleep architecture promote 
recovery from infection. Infection-induced alterations in sleep are such that 
increases in non-rapid eye movement (NREM) sleep provide energy savings, and 
short NREM-sleep bouts reduce heat loss. The reduction in REM sleep allows the 
animal to shiver. The combined changes in NREM and REM sleep facilitate the 
production of fever. Fever imparts survival value because it increases the efficiency of 
many facets of immune function and alters the host environment to make it less 
favourable for pathogen reproduction97.
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